iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 05 2022 - 3:30PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
announced today that it will report its fiscal 2022 third quarter
financial results after market close on Thursday, May 12, 2022.
iBio management will host a webcast and conference call at 4:30
p.m. Eastern Time to discuss the results and provide a corporate
update.
The live and archived webcast may be accessed on
the Company’s website at www.ibioinc.com under “News and Events” in
the Investors section. The live call can be accessed by dialing
(833) 672-0651 (domestic) or (929) 517-0227 (international) and
referencing conference ID: 2392536.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing. Its FastPharming System®
combines vertical farming, automated hydroponics, and novel
glycosylation technologies to rapidly deliver high-quality
monoclonal antibodies, vaccines, bioinks and other proteins. iBio
is developing proprietary biopharmaceuticals for the treatment of
cancers, as well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services along with Glycaneering
Development Services™ for advanced recombinant protein design. For
more information, visit www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024